Publication
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (33)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 33
- cancerAnaplastic Astrocytomacivic_curation1.00
- cancerDesmoplastic Infantile Astrocytomacivic_curation1.00
- cancerDiffuse Midline Glioma, H3 K27-Alteredcivic_curation1.00
- cancerGangliogliomacivic_curation1.00
- cancerGanglioneuroblastomacivic_curation1.00
- cancerGlioblastomacivic_curation1.00
- cancerHigh-Grade Glioma, NOScivic_curation1.00
- cancerInfantile Fibrosarcomacivic_curation1.00
- cancerInflammatory Myofibroblastic Tumorcivic_curation1.00
- cancerLow Grade Gliomacivic_curation1.00
- cancerMelanomacivic_curation1.00
- cancerMyofibromacivic_curation1.00
- cancerSolid Neoplasmcivic_curation1.00
- drugEntrectinibcivic_curation1.00
- geneALKcivic_curation1.00
- geneNTRK1civic_curation1.00
- geneNTRK2civic_curation1.00
- geneNTRK3civic_curation1.00
- geneROS1civic_curation1.00
- variantALK Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK2 Fusioncivic_curation1.00
- variantNTRK2 Fusioncivic_curation1.00
- variantNTRK2 Fusioncivic_curation1.00
- variantNTRK2 Fusioncivic_curation1.00
- variantNTRK3 Fusioncivic_curation1.00
- variantNTRK3 Fusioncivic_curation1.00
- variantNTRK3 Fusioncivic_curation1.00
- variantROS1 Fusioncivic_curation1.00
- variantROS1 Fusioncivic_curation1.00
- variantROS1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (26)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35395680
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NTRK3 Fusion5 | ||||||||
| Entrectinib | Anaplastic AstrocytomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID11853In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (2 months ol… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11848In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (3 yo) with a… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| (oncogenic) | Gliosarcoma | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID12603In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, one patient (4 yo) with Biphasic and spindled epithelioid glial neoplasm had ETV6::NTRK3 fusion. The patient received che… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| Entrectinib | Infantile FibrosarcomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11858In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| 〃 | Melanoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11857In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with melanoma … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| ROS1 Fusion1 | ||||||||
| Entrectinib | Desmoplastic Infantile AstrocytomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11850In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (3 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK3 Fusion1 | ||||||||
| Entrectinib | Desmoplastic/Nodular Medulloblastoma | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID12608In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| ROS1 Fusion3 | ||||||||
| Entrectinib | Diffuse Midline Glioma, H3 K27-Altered | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11849In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (4 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| 〃 | Low Grade Glioma | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID11855In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (8 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| 〃 | Pilocytic Astrocytoma | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID12604In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK2 Fusion1 | ||||||||
| Entrectinib | Ganglioglioma | Predictive | C | Does Not Support Sensitivity Response | 2 | accepted | EID12053In the STARTRK-NG (NCT02650401) phase 1/2 trial, a 10 year old patient with prior chemotherapy treatment who had Ganglioglioma in the Spine, with a tumor category of low grade glioma, and WHO histolog… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK2 Fusion1 | ||||||||
| Entrectinib | Ganglioglioma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11852In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (9 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK2 Fusion1 | ||||||||
| Entrectinib | Ganglioneuroblastoma | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID11854In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (7 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Entrectinib | GlioblastomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID12606In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK2 Fusion1 | ||||||||
| Entrectinib | GlioblastomaCURATED_BROADER | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID12605In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Entrectinib | High-Grade Glioma, NOS | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID12607In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| (oncogenic) | High-Grade Glioma, NOS | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID12609In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Entrectinib | High-Grade Glioma, NOS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11851In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (4 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK3 Fusion1 | ||||||||
| Entrectinib | Infantile FibrosarcomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID11859In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Entrectinib | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11856In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with inflammat… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| ROS1 Fusion1 | ||||||||
| (oncogenic) | Inflammatory Myofibroblastic Tumor | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID12611In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Entrectinib | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID12610In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| ROS1 Fusion2 | ||||||||
| Entrectinib | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID11860In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with inflammat… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| 〃 | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID11862In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with myofibrob… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Entrectinib | Myofibroma | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID11861In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| NTRK1 Fusion + NTRK2 Fusion + NTRK3 FusionNTRK1NTRK3NTRK21 | ||||||||
| Entrectinib | Solid NeoplasmCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12071In the STARTRK-NG (NCT02650401) phase 1/2 trial, 43 pediatric and young adult patients (age <22 years) with recurrent or refractory solid tumors, including primary CNS tumors, were evaluated for respo… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |